Navigation Links
Gynecologist disputes findings
Date:10/15/2010

(Phoenix, Arizona October 15, 2010) -- An internationally-recognized gynecologic oncologist at St. Joseph's Hospital and Medical Center in Phoenix, Arizona is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously.

Published in The Lancet last month, the study reported that women who received early chemotherapy for a recurrence of ovarian cancer did not live longer than those whose treatment is delayed. London-based, The Lancet is one of the world's most respected medical journals.

"While this study is a bold challenge to the assumption of early treatment, there are several significant problems with the findings," says Bradley Monk, MD, and a leader in developing new approaches to cancer treatments. "Our focus should no longer be on standard chemotherapy, but on targeted genetics-based treatments."

Dr. Monk expressed his concerns about the ovarian cancer study in an editorial in The Lancet. He and Dr. Robert Morris, of Wayne State University, wrote that finding the relevant therapy is far more important than timing when treating ovarian cancer. "The most troubling problem with the trial is that contemporary therapies were not available to most of the participants," says Dr. Monk. "This lack of availability is related not only to the chronological length of the trial (which started in 1996), but also to regulatory and financial barriers restricting access to all active compounds in the participating countries."

In the study, survival rates were not significantly different between those who started chemotherapy once a higher concentration of cancer-related proteins were detected and those whose treatment was delayed until they had clinical symptoms.

A total of 1,442 women from 59 centers around the world registered for the trial, and 529 were randomly assigned to treatment groups. About 70 percent of the women died. Of the 370 deaths, 186 occu
'/>"/>

Contact: Lynne Reaves
lynne.reaves@chw.edu
602-406-4734
St. Joseph's Hospital and Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. September 2007 Sumatran earthquakes research findings
2. Findings uncover new details about mysterious virus
3. Nearly a century later, new findings support Warburg theory of cancer
4. New research findings may enable earlier diagnosis of uterine cancer
5. Therapeutic cloning gets a boost with new research findings
6. International climate change researchers meet, review latest findings
7. Findings show insulin -- not genes -- linked to obesity
8. FANTOM findings boost for biologists
9. New findings in taste and smell
10. SRI International announces findings from new upper atmospheric radar system for scientific research
11. USC researchers present diabetes findings at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/29/2014)... Researching the safety of nanoparticles is all the rage. ... topic, examining the question of whether titanium dioxide nanoparticles ... into the body, whether carbon nanotubes from electronic products ... to be or whether nanoparticles in food can get ... Public interest is great, research funds are flowing – ...
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
(Date:10/29/2014)... One kind of stem cell, those referred to as ... There is apparently nothing that differentiates these cells from ... namely they retain the capacity to become stem cells ... liver, an organ that hosts cells that stimulate tissue ... the case of a transplant. Knowledge of the ...
Breaking Biology News(10 mins):Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3MSU partners with Detroit to investigate death scenes 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2
... , , WALL, N.J., Dec. ... BKYI), a leader in finger-based biometric identification solutions, ... world,s most respected security publications, named BIO-key International ... Access Control sub-category Biometrics. , (Logo: ...
... , , , , ... states are spending more on protecting their borders, which ... trafficking. High investment in advanced technology security and IT-based ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , New analysis from Frost & ...
... As soon as babies are born, they are susceptible ... For up to a month, their immune systems aren,t ... often minor, they can lead to serious problems if ... of Missouri researchers have pinpointed a group of depleted ...
Cached Biology News:BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3Researchers work on vaccine to improve immune system in newborns 2
(Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
(Date:10/30/2014)... October 30, 2014 Avure Technologies celebrates a ... the newest member of its fleet of high volume High ... an anniversary as we return to PackExpo this year, which ... in Las Vegas,” said Jeff Williams, CEO at Avure. “Sales ... we’re pleased to be meeting the challenges of market demand ...
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
(Date:10/30/2014)... RIDGE, N.J. , Oct. 30, 2014  Regado ... that it will hold a conference call and live ... a.m. EST to discuss its third quarter 2014 financial ... the conference call by dialing (888) 347-1165 for domestic ... call will be webcast live under the investor relations ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... Raptor,Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC ... development division, Bennu,Pharmaceuticals Inc. ("Bennu"), has acquired ... the exclusive worldwide license to EC,Cysteamine, developed ... San Diego, School of Medicine, by way ...
... Dec. 17 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: ... molecular diagnostic,tests for the early detection of ... it has started collecting patient samples,for clinical ... development,ColonSentry(TM)., In June 2006, GeneNews presented ...
... is a new drug being,studied to prevent fractures in ... 3 clinical trial using denosumab were presented,Friday evening at ... from the Seattle Cancer Care Alliance., Denosumab is ... -- specialized cells that break down bone. Because it ...
Cached Biology Technology:Raptor Pharmaceuticals Acquires Orphan Clinical Program 2Raptor Pharmaceuticals Acquires Orphan Clinical Program 3Raptor Pharmaceuticals Acquires Orphan Clinical Program 4Raptor Pharmaceuticals Acquires Orphan Clinical Program 5Raptor Pharmaceuticals Acquires Orphan Clinical Program 6GeneNews initiates patient sample accrual for validation studies of colon cancer blood test 2GeneNews initiates patient sample accrual for validation studies of colon cancer blood test 3New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment 2
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
Nucleobindin 1 [NUCB1]...
Request Info...
... cells (HSC) are well-characterized tissue-specific stem cells ... responsible for the life-long maintenance of the ... reside in adult bone marrow where hematopoiesis ... be found in cord blood, fetal liver, ...
Biology Products: